Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.910 million which missed the analyst consensus estimate of $2.521 million by 24.24 percent. This is a 2.69 percent increase over sales of $1.860 million the same period last year.
Profound Medical Q1 2024 GAAP EPS $(0.26) Beats $(0.30) Estimate, Sales $1.910M Miss $2.521M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.